Induction of neuroprotective heat-shock proteins via pharmacological Hsp90 inhibitors is currently being investigated as a potential treatment for neurodegenerative diseases. Two major hurdles for therapeutic use of Hsp90 inhibitors are systemic toxicity and limited central nervous system permeability. We demonstrate here that chronic treatment with a proprietary Hsp90 inhibitor compound (OS47720) not only elicits a heat-shock-like response but also offers synaptic protection in symptomatic Tg2576 mice, a model of Alzheimer's disease, without noticeable systemic toxicity. Despite a short half-life of OS47720 in mouse brain, a single intraperitoneal injection induces rapid and long-lasting (43 days) nuclear activation of the heat-shock factor, HSF1. Mechanistic study indicates that the remedial effects of OS47720 depend upon HSF1 activation and the subsequent HSF1-mediated transcriptional events on synaptic genes. Taken together, this work reveals a novel role of HSF1 in synaptic function and memory, which likely occurs through modulation of the synaptic transcriptome.
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurological disorder afflicting millions of individuals worldwide. Current therapeutic approaches focus on reducing Aβ levels via inhibiting βand γ-secretases, but have yielded little success clinically. 1, 2 Heat-shock protein 90 (Hsp90) is a molecular chaperone protein ubiquitously expressed throughout all tissues in the body. Some of its client proteins have been implicated in neurodegeneration. Thus, pharmacologically feasible Hsp90 inhibitors have been studied extensively in experimental conditions of neurodegenerative diseases. 3, 4 In most studies, the rationale has been premised on the presumed functions of Hsp90 inhibitors in harnessing other chaperone proteins to facilitate degradation of pathological proteins. The majority of the literature on Hsp90 describes data generated from in vitro studies, while in vivo success has been limited. [5] [6] [7] [8] [9] We have thus undertaken a different approach. While the two major chaperone proteins, Hsp70 and Hsp90, are both richly localized in synaptic compartments, 10 little is known regarding their synaptic functions. Hsp90 inhibitors bind to the N-terminal ATP-binding site, resulting in dissociation and subsequent degradation of its client proteins, which includes HSF1. [11] [12] [13] Upon Hsp90 inhibition, HSF1 is released and forms an active trimer that translocates to the nucleus. There, it binds to heat-shock response elements (HSEs) and transactivates numerous target genes (for example, hsp and synaptic genes 14 ). Here we report on a central nervous system (CNS)-permeable Hsp90 inhibitor (OS47720) that displays exceptional safety and efficacy acutely and chronically in a mouse model of AD. We also show that OS47720 strengthens synaptic function via HSF1-dependent transcriptional events (for example, bdnf genes).
MATERIALS AND METHODS Mice
All animal procedures were performed in accordance with the Animal Scientific Procedures Act and with the approval of the Institutional Animal Care and Use Committee (IACUC) at University of Tennessee Health Science Center (UTHSC). Tg2576 mice were originally purchased from Taconic (Stock #1349), Hudson, NY, USA. The HSF1 heterozygous mice were purchased from the Jackson Lab (Stock #018582), Bar Harbor, ME, USA. The iHsp70-mPlum reporter mice were generated as described, 15 and the work was performed in Spain via collaboration.
Compound administration
The solvent used for OS47720 administration consisted of 6% dimethylacetamide, 5% Tween-80 and 89% sterile H 2 O. Compound was injected intraperitoneally twice a week for the first 4 weeks, then three times a week until the end of study. Treatment started from 9 months of Tg2576 mice and lasted for 3 months, or from 12 months of Tg2576 and lasted for 6 months.
Surgical procedures
Mice were anesthetized by i.p. injection of xylazine/ketamine (13/87 mg kg − 1 ). Guide cannula (Plastics One, Roanoke, VA, USA) was implanted above the dorsal lateral ventricle using a stereotaxic instrument (David Kopf Instruments, Tujunga, CA, USA) at the coordinates: AP = − 0.37 mm; ML = +1.00 mm; DV = − 1.5 mm with respect to bregma. Cannula was mounted to the skull with medical-grade superglue (Loctite 454; Loctite, Düsseldorf, Germany). A paired dummy was fitted into each cannula to prevent clogging. Intra-CA1 injection of viruses is similar to cannulation. Instead of implanting cannulae, we used KOPF microinjection unit (Model#: 5000) to inject 1 μl of adeno-associated virus (AAV) into each of the CA1 region at the coordinates: AP = − 2 mm; ML = +1.5 mm; DV = − 1.75 mm with respect to bregma with respect to bregma, speed of 0.2 μl min − 1 . Syringe will be remained for additional 3 min for drug diffuse. Compound administration and behavior tests started at least 5 days after surgery. Virus-injected mice were housed for 3 weeks before tests.
Liquid chromatography-mass spectrometry Brain tissues were collected at 1, 2, 6 and 24 h following i.p administration of the compound. The brain samples (~250 mg per mouse) were collected and homogenized after the addition of 100 μl de-ionized water. The compounds in the brain homogenates were extracted with 0.9 ml acetonitrile and ice-cool for 20 min. The supernatants (700 μl) were transferred to a new vial, centrifuged and dried under N 2 . The dry samples were reconstituted into 140 μl of acetonitrile, mixed thoroughly and centrifuged, the supernatant was used for liquid chromatography-mass spectrometry/mass spectrometry analysis.
Liquid chromatography-mass spectrometry/mass spectrometry analysis was performed on an API-4500 triple-quadrupole system (AB Sciex, Foster City, CA, USA) with a Turbo V™ Ion Source (AB Sciex). The spraying needle voltage was set as 5.5 kV for positive mode. Curtain gas was set at 10 psi, drying gas was set at 20 psi, nebulizing gas was set at 20 psi and CAD gas was set at 7 psi. The probe heater temperature was set at 400°C. Data acquisition and quantitative processing were accomplished by the Analyst software, version 1.6.1 (AB Sciex). Sample solution (5 μl) was injected into a Shimadzu (Canby, OR, USA) Nexera UPLC system. Multiple reaction monitoring mode, scanning m/z 457.0 → 194.1 (positive mode), was used to obtain the most sensitive signals. Chromatographic separation of the analytes was performed using a Luna PFP column (50 × 2.0 mm internal diameter and 3.0 μm particle size; Phenomenex, Torrance, CA, USA) with a guard column, applying gradient elution. Mobile phase A: 0.01% formic acid in water; B: 0.01% formic acid in methanol. 0-0.5 min: 2% B; 0.5-0. 
In vivo imaging of dendritic spines and data analysis
The surgical procedure for chronic transcranial two-photon imaging and data analysis with NIH ImageJ software (Bethesda, MD, USA) has been described previously. 16 Filopodia were identified as long, thin structures without enlarged heads, and the rest of the protrusions were classified as spines. Spines were considered the same between two views based on their spatial relationship to adjacent landmarks and spines. Spines in the second view were considered different if they were more than 0.7 μm away from their expected positions based on the first view. More than 150 spines were analyzed from each animal to calculate spine formation and elimination. The rate of spine formation or elimination was calculated as the number of spines formed or eliminated divided by the number of spines existing in the first view.
In vivo recording of cortical-hippocampal network
Thirteen mice (B6, male, 18-month-old) were divided into OS47720 (n = 7)-and vehicle (Veh, n = 6)-treated groups ( Supplementary Table 1 ). Animals were surgically prepared for unilateral intraventricular infusion (IVI) and awake head-fixed recordings of local field potentials (LFPs) from the contralateral hemisphere. The infusion of OS47720/Veh (2 μl) through an implanted cannula in the lateral ventricle was completed over 10 min. LFPs in the CA1 region of the hippocampus and the prefrontal cortex (PFC) were recorded during three time periods: 10 min pre-IVI; 10 min post IVI; and 1 day post IVI.
During LFP recording, the depths of recording position in CA1 were determined by the presence of the characteristic high-frequency ripple activity that was synchronous across the two recording sites. The recording locations were also confirmed by electrolytic lesions at the end of experiments and by anatomical verification in Nissl-stained sections. Each animal's breathing was continuously monitored through a thermistor positioned near one nostril. Breathing signals were used for offline LFP data selection. In the present study, data recorded during resting state (that is, a smooth breathing rhythm with a stable rhythm below 4 Hz) were selected for further analyses.
LFP data from the two electrodes in CA1 (separated by 0.3 mm) and the one in the PFC were selected for coherence analysis. Five continuous resting-state LFP signals (1 min each) were extracted from each of the three time periods (pre-, immediately after IVI and 1 day after IVI) and exported as Matlab files. Using scripts written in house (Matlab, R2015a), LFPs recorded within CA1 and in CA1 and PFC were analyzed for the magnitude-squared coherence (Matlab function code: mscohere).
Immunocytochemistry and dendritic spine quantification
Rat hippocampal neurons (day in vitro 21) at low density were fixed by 4% paraformaldehyde, permeabilized by 0.1% Triton X-100, immunostained for synaptic proteins and visualized using a confocal fluorescence microscope. Anti-PSD95 (1:100; Santa Cruz Biotechnology, Dallas, TX, USA), anti-Synapsin I (1:200; Cell Signaling Technology) antibodies and 4,6diamidino-2-phenylindole (Roche, Basel, Switzerland.) were used. Synaptic clusters were calculated as the average number of clusters per 10 μm of dendritic length. AAV1-YFP was used to highlight dendritic spines of hippocampal neurons (day in vitro 21) at low density. Dendritic spines of primary and secondary basilar dendrites were counted and analyzed. Images were captured under a confocal microscope (Olympus America, Center Valley, PA, USA).
Synaptosomal preparation and RNA analysis (quantitative reverse transcription-PCR)
Total RNA was extracted from cells by using Trizol reagent (Life Technology, Carlsbad, CA, USA). For synaptosomal RNA, pooled mouse hippocampi were homogenated into 10 volumes of ice-cold HEPESbuffered sucrose (0.32 M sucrose and 4 mM HEPES (pH 7.4)) containing a RNase inhibitor. Centrifuge the homogenate at 1000g at 4°C to remove the pelleted nuclear fraction (P1) and unbroken cells. The resulting supernatant (S1) from further centrifugation at 10 000g for 15 min at 4°C yielded the crude synaptosomal pellet (P2). P2 was resuspended into 0.32 M sucrose and layered onto 4 ml of 1.2 M sucrose. Centrifuge at 38 000 r.p.m. in SW51 and collect gradient interphase. Synaptosomal interphase was diluted with 0.32 M sucrose and then carefully layered onto 4 ml of 0.8 M sucrose. Centrifuge again to pellet synaptosomes. The pellet was then lysed in Trizol for RNA preparation. The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) was used to synthesize the first-strand cDNA from the samples with an equal amount of RNA. Synthesized cDNAs were then amplified and analyzed on Real-Time PCR Systems (Invitrogen, Carlsbad, CA, USA) using SYBR Green MasterMix (5 Prime, Gaithersburg, MD, USA). Primers used were listed in Supplementary Table 2 .
Histology and immunohistochemistry
Mice were heart-perfused by saline and 4% paraformaldehyde, and postfixed in 4% paraformaldehyde overnight. Mouse brains were paraffinembedded, and 5-μm sections were deparaffinized by passing through 100% xylene and rehydrated through serial dilutions of ethanol (100, 95 and 75%). Hematoxylin and eosin staining was performed and images were captured under a light microscope. For optimal cutting temperature compound embedding, perfused brains were cryoprotected by 30% sucrose infiltration and then sectioned at 10 μm using a cryostat (Leica Biosystems, Wetzlar, Germany). Anti-HSF1 (1:100; Cell Signaling Technology), anti-β-Amyloid (clone 4G8; 1:100; Covance, Princeton, NJ, USA), anti-NeuN (1:100; EMD Millipore, Billerica, MA, USA), anti-GFAP (1:1000; Sigma) and anti-Iba1 (1:500; Wako Chemicals USA, Cape Charles, VA, USA) antibody were used and nuclei were stained with 4,6-diamidino-2-phenylindole.
Protein analysis by western blots
Western blots were performed as previously described. 17 Antibodies were used as follows: rabbit anti-Hsp90, cHsp70, Hsp40, Hsp27, HSF1, PSD95 and Synapsin I (1:1000; Cell Signaling Technology); mouse anti-iHsp70 (1:1000; Enzo Life Sciences, Farmingdale, NY, USA); rabbit anti-brain-derived neurotrophic factor (anti-BDNF; 1:500; Santa Cruz Biotechnology); mouse anti-β-actin (1:10 000; Sigma-Aldrich); rabbit anti-Synaptophysin (1:2000; Chemicon/EMD Millipore, Billerica, MA, USA); and anti-mouse IgG and anti-rabbit IgG horseradish peroxidase-conjugated antibodies (1:5000; Sigma-Aldrich).
Amyloid-beta ELISA
Cortex tissues were collected and processed using mouse amyloid-beta 40 ELISA kit and amyloid-beta 42 ELISA kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's protocol, with additional guanidine HCl to extract insoluble amyloid from tissues.
Behavior tests
Contextual fear conditioning. Contextual fear conditioning test was conducted as previously described. 14 Open-field test. Each animal was individually placed in a novel open-field arena (in cm: 47 L × 37 W × 20 H; 900 lux at the center; AccuScan Instruments, Columbus, OH, USA) for 10 min while being recorded by an overhead camera. Total locomotor activity was measured by beam breaks of the equipped 16 infrared beams. The footage was then analyzed by an automated tracking system (EthoVision XT software; Noldus, Wageningen, The Netherlands). The time spent in the center (25% of the field) was measured as a potential indicator for anxiolytic behavior.
Elevated plus maze. The elevated plus maze apparatus is a '+'-shaped maze with two facing open arms, two facing closed arms and a center area (arm/wall sizes, in cm: 50 L × 10 W × 30 H; runway height from floor: 55 cm). Each mouse was allowed to freely explore the maze for 5 min. The preference for being in open arms over closed arms (expressed as a percentage of time spent in the open arms) was calculated to measure anxiety-like behavior.
Novel object recognition. The task was conducted in an open arena (in cm: 47 L × 37 W × 20 H) with two objects in HSF1 heterozygous mice. During habituation (day 1), mice were allowed to freely explore the arena. On day 2, mice were exposed to two identical objects (red cubes) placed in the center of field. On day 3, one object was replaced by another novel object (blue triangle). Each test lasted for 10 min. Time spent in exploring each object was recorded. Exploration time and discrimination index were calculated.
Cross maze. Spontaneous alternation rates were assessed using a cross maze. Cross maze was conducted in a '+'-shaped maze with four white and opaque plastic arms with walls (arm/wall sizes, in cm: 50 L × 10 W × 30 H). Briefly, animals were introduced from a fixed entry located in one of the four arms, and were allowed to freely explore four arms for 5 min. An alternation is defined as going into each of the four arms without repeating an arm. The number of alternations is then divided by the number of arm choices minus three to get the alternation rate, which is a measure of working memory.
Morris water maze. Water maze tests were conducted in a 118-cm diameter round tank, filled with 25°C opaque water using non-toxic white tempera paint (Crayola). During the test, mice were first trained to learn swimming and to find a cued (visible by a black acrylic ball 30 cm above the platform) escape platform (10 cm diameter; 0.5 cm above water surface) for 3 days, then underwent 10 days of hidden platform session (0.5 cm below water surface) and 1 additional day of probe trial session (platform removed). Two days of rest were given before mice went to hidden platform session. During the hidden platform session, swimming path and distance were recorded and calculated as measures of spatial and learning memory. During the probe trial session, platform crossings and time spent in a 40-cm zone centered on the former platform location were recorded as measures of spatial memory.
Statistical analysis
All statistical analysis was performed by Student's t-test for two groups' comparison, or one way analysis of variance, followed by Tukey's HSD (honest significant difference) post hoc tests for three or more groups' comparison. All quantitative data are presented by means ± s.e.m. The asterisks indicate significant difference versus control as follows: *Po0.05; **P o0.01; and ***Po0.001.
RESULTS

OS47720 effectively induces activation of hippocampal HSF1 and the expression of synaptic proteins in vivo
The Pochoxime series of Hsp90-inhibiting compounds were reported to display feasible CNS permeability and minimal systemic toxicity in reducing glioma progression upon 3-month treatment in mice. 15, 18, 19 We compared the prototypic geldanamycin (GA, systemically toxic) and 17-AAG (limited CNS permeability) with Pochoxime C (OS47720) ( Figure 1a ) for hepatotoxicity, each at 100 mg kg − 1 via a single i.p. injection. The mice receiving GA died within 24 h while the remaining mice continued receiving daily injections of 17-AAG or OS47720. By the fifth day, 3/4 of the mice receiving 17-AAG demonstrated signs of severe lethargy and organ damage, while hematoxylin and eosin staining showed no traceable hepatic and nephric alterations with OS47720 ( Figure 1b and Supplementary Figure 1) .
Neuronal exposure to 100 nM of OS47720 induced nuclear translocation, indicating rapid HSF1 activation, as similarly seen with 17-AAG 14 (Supplementary Figure 2 ). This was followed by sustained induction of multiple HSPs and synaptic markers, with effects lasting 24-48 h ( Supplementary Figure 3) . Confocal microscopy demonstrated that OS47720 also caused a nearly twofold increase in synapsin I and PSD95 clusters, and significantly protected synapses against soluble Aβ-impaired structural damage ( Supplementary Figure 4) .
Using liquid chromatography-mass spectrometry, we found that 1 h after a single i.p. injection at 100 mg kg − 1 , OS47720 reached a maximum concentration in the brain of~1000 ng g − 1 and declined rapidly over the next 2-24 h (Figure 2a ). To determine the duration of OS47720's effects in mouse brain after a single i.p. injection, we measured induction of iHsp70 and PSD95 levels in various tissues over two days (Figure 2b ). Although the iHsp70 protein is most abundant in skeletal muscle, Hsp90 inhibition elicited the greatest response in liver, as evidenced by the most marked induction of iHsp70 shown at 2 h. The hippocampi expressed much lower levels of iHsp70 from Hsp90 inhibition, although PSD95 was markedly elevated. It should be noted that lumbar cord tissue did not demonstrate a response to the Hsp90 inhibitor, which is consistent with the idea of failed stress response in motor neurons/amyotrophic lateral sclerosis (ALS) mice as previously reported. 8 We also observed a longlasting OS47720 effect on HSF1 nuclear translocation, most prominently as an increase in the HSF1 immunoreactivity in the pyramidal neurons of CA1, in cytoplasm and nuclei (4,6-diamidino-2-phenylindole/blue), peaking starting from 24 h, and, to a lesser degree in neurons of the CA3 region and cortex ( Figure 2c ). We confirmed that the HSF1 induction is indeed transcriptionally active by injecting OS47720 i.p. to young iHsp70 promoter-mPlum reporter mice. 20 This induced a long-lasting activation of the iHsp70 promoter, again most prominently in the CA1 regions and maintaining kinetics identical to those of HSF1 (Supplementary Figure 5 ), although the response was weaker than that in liver. Despite a relatively weak heat-shock-like stress response, the induction of synaptic proteins is strong and long-lasting in hippocampi. These findings imply a potentially important role of HSF1 in hippocampally mediated functions such as learning and memory.
OS47720 promotes dendritic spine formation in cortex and coherence of local field potential in hippocampus Memory is closely associated with dendritic spine dynamics (including elimination and formation) in long-term memory. 21, 22 Using transcranial two-photon microscopy, we examined the effect of OS47720 on the dynamics of postsynaptic dendritic spines of Layer V pyramidal neurons in the motor cortex of Thy1-YFP-H line mice (Figure 3a ). We found that in young adult mice, a single i.p. injection of OS47720 significantly increased the rate of spine formation (12.9 ± 1.2% versus 6.7 ± 0.5%, P o 0.001) over 2 days. No significant difference in spine elimination was observed between OS47720-and vehicle-treated animals (8.1 ± 1.3% versus 7.8 ± 0.8%, P = 0.660) (Figures 3b and c) . These results indicate that OS47720 was effective in promoting synapse formation in vivo, an idea which is consistent with our in vitro findings ( Supplementary Figures 4e and f) .
To determine whether OS47720 could functionally affect neuronal activity in memory-related hippocampal and corticalhippocampal networks of aged mice, we performed simultaneous extracellular recordings of LFPs in the PFC and hippocampal CA1 region of 18-month-old mice. Two electrodes (spaced 0.3 mm apart) were placed in CA1 and one electrode in the PFC ( Supplementary Figure 6a ). This allowed assessment of coherence of neuronal activity within CA1 and between the PFC and CA1.
Here we analyzed coherence of LFP activity for three 10-min time windows: immediately before and after OS47720 or vehicle treatment and 24 h after treatment.
In our recordings in CA1 characteristic sharp-wave-ripple complexes 23 were frequently observed and were synchronized between the two recording locations (Figures 3d-f ). The presence of sharp wave ripples was used to identify CA1-recording locations during experiments. Recording sites were also confirmed anatomically for a subset of mice using small electrolytic lesions placed at the end of recording sessions ( Supplementary Figure 6b ). Coherence of LFP activity was compared before and after OS47720 or vehicle infusion. Immediately following OS47720 or vehicle treatment, there were no significant effects of OS47720 on coherence (Figures 3g-i) . However, 24 h after treatment coherence in CA1 was significantly increased for frequencies between 20-30 and 110-120 Hz (Figure 3g ). There also was a trend for LFP coherence in CA1 to be elevated across all frequency bands tested (1-220 Hz). Vehicle injection did not affect coherence within CA1 at either of the two post-injection time points (Figure 3h ). Coherence of LFP activity recorded from two sites within the hippocampal CA1 region of OS47720 and vehicle groups, respectively. Coherence was calculated for 10-min data segments recorded immediately before (blue traces) and immediately after injections (red traces) and 24 h after injections (green traces). Brackets mark frequency bands where OS47720 treatment significantly altered CA1 LFP coherence compared with pre-injection control (*Po 0.05, two-sample t-test: comparisons between pre-and 1 day post OS47720/vehicle). Vehicle treatment had no effect on CA1 LFP coherence. (i) LFP coherence between CA1 and PFC. Trace color codes are the same as in g and h. Brackets are as in g and mark frequencies where OS47720 treatment significantly altered coherence of CA1-PFC LFP activity. Coherence data are expressed in mean ± s.e.m.
Functional interactions between CA1 and PFC have been studied extensively, particularly in the context of memory formation. [24] [25] [26] We measured the coherence, the degree of phase-locking of oscillatory neuronal activity at two recording sites corresponding to these two brain structures that has been most implicated in cognitive processes. In the OS47720-treated group, LFP coherence between the CA1 and PFC was significantly increased at frequencies between 190 and 200 Hz and decreased at frequencies between 70 and 80 Hz (Figure 3i ). Vehicle injection had no effect on coherence between the CA1 and PFC ( Supplementary Figure 6c ).
Chronic treatment with OS47720 rescues spatial learning and memory in acute Aβ and symptomatic Tg2576 mice The therapeutic effect of OS47720 was first evaluated in an acute model of Aβ-impaired contextual conditioned freezing memory. In young C57BL/6 mice, Aβ (from 7PA2 conditioned medium 14 ) was administered 5 days after daily OS47720 injection, three times via intracerebroventricular injection through the implanted cannula at the indicated time points (Supplementary Figure 7a) . The acquisition of freezing behavior was recorded during the first day of training, and the contextual fear retention was recorded 24, 48 and 72 h later. OS47720 treatment improved contextual freezing memory, reaching statistical significance at the 72 h time point ( Supplementary Figure 7b ). Protein analysis revealed restored PSD95 and mature BDNF following OS47720 treatment ( Supplementary Figures 7c and d) . Profiling of various BDNF isoforms indicated that Aβ reduced the majority of BDNF isoforms in hippocampal synaptosomes, while they were largely rescued by OS47720, some even restored to a higher level when compared with the control (Supplementary Figure 8) .
We then tested OS47720 (100 mg kg − 1 i.p. every 2 days for 3 months) on early symptomatic Tg2576 and littermate control mice starting from 9 months of age. This dosage was determined based on a previous study 19 and our dosing experiment on B6 mice. Over the course of treatment there was no significant weight loss and no group differences in weight gain ( Supplementary Figures 9a and b) . Moreover, there were no group differences on any measure of locomotor activity or anxiety (Supplementary Figure 10) . Working memory was greatly impaired in the Tg2576 group, as indicated by significantly lower alternation rate on the cross maze test, and this was almost completely rescued by OS47720 (Figures 4a and b) .
The Morris water maze test was used to measure spatial and learning memory. Distance was used as a dependent measure because of a slightly (but nonsignificant) faster swimming speed in the Tg-Veh group, compared with the other three groups. Mice in all groups readily found the cued platform (Figure 4c ). On the hidden-platform training, there were significant effects of genotype and drug, and a significant genotype × drug interaction. Vehicle-treated Tg mice were significantly impaired relative to their non-Tg counterparts (Figure 4c ), consistent with previous reports in these mice. 27 OS47720 treatment rescued this spatial learning impairment in the Tg group, demonstrated by significantly shorter swim paths. OS47720 treatment did not improve spatial learning and memory in the non-Tg mice, and there was no genotypic difference in the OS47720-treated mice (Figure 4c ). A probe trial was conducted 24 h after the last hidden-platform session to assess memory for the former platform location. Time spent in a 40-cm zone centered on the former platform location was used as an index of spatial memory as it was a more precise measure in the target quadrant (Figure 4e ). The vehicle-treated transgenic mice did not spend significantly more time in the target zone, when compared with the mean of the other three zones (Figure 4d) . Similarly, these mice did not discriminate between the former platform location and equivalent positions in the other three quadrants. In contrast, mice in the other three groups showed a selective search for the targets. Heat maps show a more defined swim path in OS47720-treated groups, indicating superior spatial reference memory (Figure 4f ). Consistent with our in vitro data, the expression levels of iHsp70, synaptic proteins (synapsin I and PSD95, but not SNAP25) and BDNF were significantly increased in the hippocampi of Tg2576 mice after chronic OS47720 treatment (Figures 4g and h) .
We repeated OS47720 testing on mid-stage symptomatic Tg2576 from 12 to 18 months of age and observed very similar results. There was a slight decrease in body weight (10-14% on males and 5-12% on females) over a 6-month treatment course in all vehicle-and OS47720-treatment groups, suggesting mild toxicity or stress caused by the vehicle (Supplementary Figures  9c and d) . Similar to the previous results, the deficit of working memory in the Tg-Veh group was again significantly improved by OS47720 treatment in Tg mice, with no difference in total entries among all groups (Figures 4i and j) . The Morris water maze test revealed impaired long-term spatial learning and memory in the Tg-Veh group, which was significantly improved in the Tg-OS47720 group to the point where memory was comparable to that of the non-Tg and non-Tg-Veh groups ( Supplementary  Figure 4k ). During probe trial sessions, the Tg-Veh group lacked preference in the target search, while the other three groups selectively searched for the target zone ( Supplementary Figure 4l ). Vehicle treatment had no effect on cross maze or Morris water maze tests ( Supplementary Figures 7i-l) . Similarly, chronic OS47720 treatment again rescued the expression levels of HSPs (iHsp70 and Hsp40), PSD95 and BDNF (Figures 4m and n) . Notably, HSF1 expression was also rescued by OS47720 in both cohorts to a level even higher than that of non-Tg (Figures 4g, m) . End-point studies of Aβ (4G8) levels revealed that OS47720 did not significantly reduce Aβ plaques (immunofluorescence staining) or soluble and insoluble Aβ (ELISA) or neuroinflammation (stained with astrocytes maker GFAP and microglia maker Iba1) in the brain after chronic treatment ( Supplementary Figure 11) , nor did the levels of transthyretin 28 differ among all four groups ( Supplementary Figure 12) . Taken together, OS47720 improved memory, including short-term working memory and long-term spatial and learning memory, in both early-and mid-stage Tg2576 mice.
OS47720 exhibits neuroprotection and memory amelioration via HSF1
We hypothesized that OS47720 improves memory through activation of HSF1. We first microinjected an HSF1-specific pharmacological inhibitor, KRIBB11, 29 into mice at various time points during fear training. Strikingly, triple injections of KRIBB11 impaired contextual memory even more severely than did Aβ administration (Figures 5a and b) . This was accompanied by marked reductions of HSF1, HSPs and various synaptic proteins (Figures 5c and d) . Overexpression of a constitutively active hsf1 (AAVH-BH) 30 or AAV-shRNAhsf1 to downregulate hsf1 by AAVs resulted in opposite consequences of heat-shock response (for example, iHsp70), synaptic proteins (PSD95) and BDNF (Figures 5e and f) . Furthermore, The AAV-mediated downregulation of HSF1, specifically in the hippocampal region and DG (Figure 5g ), diminished contextual memory at both 48 and 72 h after training, which could not be rescued by OS47720 (Figures 5h  and i) . In contrast, OS47720-treated mice had slightly higher basal contextual memory at these time points. An end-point study of the altered proteins revealed abolished Hsp40, PSD95 and mature BDNF by AAVshRNAhsf1 administration, changes that were not restored by OS47720 treatment (Figures 5j and k) . In addition, HSF1 heterozygous knockout mice showed impaired working memory, recognition memory and locomotor activity, but not anxiety ( Supplementary Figure 13) . These results indicate that HSF1 has a significant role in memory and that the beneficial effects of OS47720 require functionally active HSF1. To determine whether requirement of HSF1 is more prevalent in the initial stage of memory acquisition and consolidation or for all stages (including retrieval and extinction), we administered KRIBB11 1 h before and 1, 3, 6, 8 and 24 h after training. The most significant abrogating effect was observed at 1 h post training, and to a lesser degree at 3 and 6 h post training. No effect was observed when injected at 8 or 24 h post training ( Supplementary Figure 14) .
These results indicate that HSF1 is required for the initial stage of memory consolidation or retrieval. OS47720 effect is mediated by activated CREB bypassing cAMP/ PKA and PI3K/Akt pathways To determine whether OS47720 induced BDNF upregulation via the classic cAMP-PKA-CREB pathway, cAMP levels were measured (e) Schematic diagram shows target zone surrounding the location of the missing platform, as well as a non-target zone along the pool. (f) Representative images of the heat map from each experimental group during the probe session. (g) Representative images (four mice from each group) of western blot analysis after Morris water maze. HSF1, heat-shock proteins (iHsp70 and Hsp40), synaptic proteins (PSD95, synapsin I and SNAP25) and brain-derived neurotrophic factor (BDNF) were tested in four groups. (h) Statistical analysis of the western blot data presented in g. n = 6. (i-n) Effects on mid-symptomatic Tg2576 mice after 6-month treatment (12-18 months). n = 11-13. Each group includes half males and females. (i, j) Total entries and alteration rate (%) representing working memory on cross maze calculated as above. (k, l) Morris water maze test in cued session, hidden platform session and probe trial session. (m, n) Western blot analysis on postmodern tissue followed by quantification. n = 5-6. One-way analysis of variance followed by Tukey's post hoc test, non-Tg-Veh vs non-Tg-OS47720, Tg-Veh vs non-Tg-Veh, Tg-Veh vs Tg-OS47720, *Po 0.05, **Po 0.01 and ***P o0.001. Error bars show means ± s.e.m.
in cultured hippocampal neurons. OS47720 did not alter intracellular cAMP production even when a priming concentration of forskolin was included (Supplementary Figure 15a) . The lack of a role of the cAMP-PKA-CREB, MAPK and PI3K pathways in the formation of dendritic spines was confirmed by pharmacological inhibitors (that is, RpcAMP and H89, U0126 and LY294002; Supplementary Figure 15b ). These results are consistent with our previous reports showing reduced Akt levels upon Hsp90 inhibition in neurons. 15 A CaMKII inhibitor did reduce the effect of OS47720 on dendritic spines. Statistical analysis revealed significant loss of dendritic spines using KN93, a selective CaMKII inhibitor, with or without co-treatment of OS47720, while no effect was observed by using its inactive derivative, KN92 ( Supplementary Figure 15c) .
DISCUSSION
While Hsp90 inhibitors have been investigated as anticancer agents over the past 2 decades, 31, 32 and as therapeutic agents for neurodegenerative diseases over the past decade, 3, 4 they have yet to demonstrate any clinical success. In addition to systemic toxicity, brain penetrability represents another major challenge for therapeutic development of the drug for CNS applications. Although there is evidence of two CNS-permeable Hsp90 inhibitors successfully reducing tau aggregation with feasible toxicity profiles, they were tested either too acutely (single i.p. injection) 33 or too briefly (7 days). 6 Herein, we have presented data demonstrating successful chronic (6 months) treatment of symptomatic Tg2576 mice with a CNS-permeable and non-toxic Hsp90 inhibiting compound. Notably, we demonstrate a unique mechanism of Hsp90 inhibition in preserving synaptic structures and functions. The potential therapeutic implications of these findings are boundless, and are only further encouraged by the remarkable pharmacokinetics and pharmacodynamics of this compound (OS47720).
In the past decade, the stress response to heat or Hsp90 inhibitors is generally considered blunted in neurons. 34, 35 While much of the data were generated through neuroblastoma or rodent primary neuronal culture models, there is a dearth of in vivo data until recently. 36 Our ex vivo data ( Supplementary  Figure 5b ) on the iHsp70 reporter mice after either single or continual OS47720 treatment also indicate a relatively weakened, but not blunted, neuronal HSF1/iHsp70 response in the brain relative to the liver and muscle. It was observed that the hippocampal CA1 region (versus CA3) demonstrated the greatest HSF1/iHsp70 response, while spinal cord motor neurons demonstrated almost undetectable responses (Figure 2b ). This finding is consistent with previous reports that motor neurons have a high threshold for activation of HSP genes, which may explain why this neuronal type is the most vulnerable and undergoes the most rapid degeneration. 8 There are several possibilities for the weak heat shock responses in neurons, which may not be mutually exclusive: (1) the presence of intrinsic repressor(s) at the HSE sites;
(2) HSF1 itself is differently regulated in neurons; and (3) the existence of intrinsically inert neuronal iHsp70 promoter. Hippocampal CA1 region has long been recognized to be most vulnerable to stress response (for example, ischemia) presumably due to the 'glucocorticoid oversensitivity', 37 the most prominent HSF1 activation in CA1 may represent neuronal attempt to perverse the most important functions rendered by this subregion. These possibilities warrant further investigation.
In addition to heat-shock proteins, our work highlights HSF1mediated transcriptional upregulation of multiple synaptic genes, which include genes coding for synapsin I, synaptophysin, PSD95, BDNF, as well as several immediate early genes. On the basis of the consensus sequences of HSF1-binding elements (HSEs), we identified potential HSEs in the promoter regions of these genes (Supplementary Table 2 ). Among them, we provide evidence of direct binding of HSF1 to an HSE1 site in close vicinity to the key CREB binding site (CRE) in bdnf promoter I, which was upregulated 1 h post-foot shock. In addition, several immediate early genes were also induced at this time point. Surprisingly, the expression of SNAP-25, a member of the SNARE family and synaptosomalassociated protein of 25 kDa at presynapses, was not reduced in 12 months Tg2576 mouse brain (Figure 4g ), nor its expression was upregulated by HSF1. Together, these results imply that HSF1 is another principle transcriptional factor, which is required for gene upregulation during consolidation or retention of fear contextual memory via its interplay with CREB. This concept is also supported by the data demonstrating significant abrogating effects of the HSF1 inhibitor administered 1 h post training (Supplementary Figure 14 ). We believe that HSF1 has a regulatory role in reshaping the synaptic transcriptome on a genomic scale ( Supplementary  Figure 16 ), which ultimately contributes to neurodegeneration. Indeed, the HSF1-regulated transcriptome was found to be impaired by an aggregated huntingtin (Htt) protein, which may participate in the neurodegeneration observed in Huntington's disease. 38 OS47720 mediates its therapeutic effect in Tg2576 mice via highly novel synaptic strengthening mechanisms via modulation of Hsp90. The unique sustained (43 days) induction of synaptic genes/protein expression after a single i.p. injection of OS47720 may be attributed to multiple mechanisms, including transcriptional regulation. This is not surprising given the large pool (4800) of cellular proteins identified as Hsp90 client proteins, many of which may include membrane receptors necessary for neuronal transmission (for example, AMPAR), 39 as well as proteins regulating post-transcriptional microRNAs and translational processes. Indeed, we observed markedly enhanced spine formation 24-48 h following a single injection of OS47720, which was confirmed by two-photon microscopic live imaging in young mice. Notably, we demonstrated that in healthy aged mice (18 months) OS47720 alters coherence of LFP activity within the hippocampal CA1 region and between CA1 and the PFC for beta (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , gamma (30-100 Hz) and higher-frequency (190-200 Hz) oscillations. Coherence measures the degree of phase-locking of oscillatory neuronal activity at two recording sites and is an indicator of neuronal communication between brain structures that has been implicated in cognitive processes. [40] [41] [42] Abnormalities in coherence of brain activity have been shown to be associated with AD, both in humans 43, 44 and in a mouse model 45 of the disease. It has been proposed that measures of coherence of brain activity could serve as a biomarker for AD. 46, 47 LFP coherence between the PFC and CA1 within the gamma frequency range has been strongly implicated in attention, working memory and memory consolidation. 26, 48 Our findings suggest that the rescue of memory deficits by OS47720 treatment observed in AD mice is indicative of OS47720 effecting coherent neuronal activity between the PFC and CA1.
Neurodegenerative diseases are commonly characterized by aberrant formation of pathological protein aggregates. While the clearance of misfolded proteins following Hsp90 inhibition is ill-defined, it is generally accepted that it requires induction of a heat-shock-like response that results in HSF1-mediated upregulation of other chaperone proteins such as iHsp70 and its co-chaperones (for example, Hsp40/DNAJ, Hsp27 and so on). Of note, OS47720 did not cause any observable effects in reducing amyloid Aβ load in Tg2576 mice after 3-or 6-month treatments, despite various reports of anti-Aβ effects by other Hsp90 inhibitors. 49, 50 These seemingly contradictory results reflect intrinsic differences between in vitro and in vivo experimental systems, as the majority of reports indicating Aβ-reducing effects were derived from in vitro studies, which lack the proper neuroglial microenvironment. We believe that the lack of Aβ reduction after chronic OS47720 administration is due to the modest induction of stress responsive proteins (iHsp70 and Hsp40) by this drug (Figures 4g, h , m, n). While it has been acknowledged that high levels of iHsp70 (and perhaps other co-chaperones) facilitate Aβ degradation, 51 such as in the cases of Hsp70 overexpression in AD mice crossed with an Hsp70 transgenic 52, 53 or DNAJ (Hsp40) overexpression on Htt degradation in R6/2 mice, 54 it appears that such high expression levels of chaperone proteins is not achievable via Hsp90 inhibition in mice.
HSF1 dysregulation in neurodegeneration is largely unstudied. In aged Tg2576 mice, we found significantly reduced (~20%) protein expression of HSF1 in the hippocampi relative to their non-Tg littermates (Figures 4g, h, m, n) . Chronic OS47720 treatment not only normalized HSF1 expression but also elevated basal levels of expression. That an Hsp90 inhibitor can upregulate the HSF1 gene and its expression has not yet been reported. We have evidence supporting the role of an Hsp90 inhibitor upregulating the hsf1 gene in neurons (Liao, unpublished data). We recently discovered that loss of HSF1 protein is due to ubiquitinproteasome system-mediated protein degradation in primary patient brains with Lewy's bodies. This was caused by proteotoxic stresses from misfolded and aggregated proteins such as αsynuclein, which may contribute to α-synucleinopathy. 55 Although soluble Aβ can also induce HSF1 degradation in neuronal cellular cultures, as well as in amyloid precursor protein-overexpressing FAD transgenic mice, the extent of HSF1 loss is not as severe as in the cases of amyotrophic lateral sclerosis, alpha-synuclein or R6/2 Htt transgenic mice (Liao, unpublished data).
HSF1 is the most important master stress response regulator, yet its role and regulatory mechanisms in CNS disease remains illdefined. Our restudy has sought to address this void in neurodegenerative research. HSF1 expression levels are reduced in the granule Purkinje neurons in AD rat cerebellum, and AAVdelivered HSF1 into the brain stem reversed neurodegeneration. 56 We believe that pharmacological agents that can activate and stabilize HSF1 protein expression and function hold therapeutic promise for treating a chronic neurodegenerative disease such as AD. Among the four currently known CNS-permeable Hsp90 inhibitors, [6] [7] [8] 33 OS47720 is the only Hsp90 inhibitor compound that has demonstrated exceptional in vivo performance in AD mice, including an apparent lack of systemic toxicity at therapeutically relevant dosage over a chronic period of time (see summary in Supplementary Table 3 ). The notion of currently limited success with the other CNS-permeable compounds prompts us to consider a potential fundamental difference between AD and other neurodegenerative diseases (that is, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis). It appears that AD is more of a synaptic disease 57,58 than one caused by severe proteinopathy, an idea that becomes more attractive when considering the 2-3-decade window of chronic neurodegeneration in AD compared with a o2-year disease onset of an amyotrophic lateral sclerosis patient. We believe our work is the first demonstrating feasibility of treating a chronic dysfunctional synaptic disease such as AD with a pharmacologically feasible Hsp90 inhibitor (OS47720). Most notably, it is effective on treating symptomatic mice with significant amyloid plaque load via protecting synapses. Hence, this work demonstrates translational significance. In particular, by combining Hsp90 inhibitor-mediated synaptic protection with other anti-amyloid treatment (for example, β-secretase inhibitors), it may offer a viable treatment option for treating symptomatic AD patients.
